Search

CRISPR Therapeutics AG

Затворен

СекторЗдравеопазване

49.37 -0.72

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

49.02

Максимум

49.52

Ключови измерители

By Trading Economics

Приходи

32M

-91M

Продажби

8.7M

10M

EPS

-0.94

Марж на печалбата

-895.334

Служители

393

EBITDA

7.3M

-111M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+42.36% upside

Дивиденти

By Acuity

Следващи печалби

9.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

236M

4.8B

Предишно отваряне

50.09

Предишно затваряне

49.37

CRISPR Therapeutics AG Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

23.10.2026 г., 21:11 ч. UTC

CRISPR Therapeutics AG shares rose in after-market trading, reflecting broader market gains amid strong business activity growth and improved consumer sentiment.

22.10.2026 г., 23:56 ч. UTC

CRISPR Therapeutics AG is trading slightly higher in after-market hours, reflecting a modest increase since Thursday's close while remaining below its 20-day moving average.

21.10.2026 г., 23:01 ч. UTC

CRISPR Therapeutics AG shares are trading modestly lower in after-market hours, reflecting unusual volatility and remaining significantly below their 20-day moving average.

20.10.2026 г., 23:06 ч. UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, recovering from earlier fluctuations but remains below its 20-day moving average.

19.10.2026 г., 23:01 ч. UTC

News

CRISPR Therapeutics AG CFO Raju Prasad steps down, with A.J. Silver appointed as his successor, as the company continues to face after-market pressure.

16.10.2026 г., 23:06 ч. UTC

CRISPR Therapeutics AG is down in after-market trading, having retraced from earlier gains and currently sitting just below Friday's close.

15.10.2026 г., 23:26 ч. UTC

Correlated Moves
News

UBS initiated coverage on CRISPR Therapeutics AG with a Neutral rating and set a price target of $52, announced after the market closed.

14.10.2026 г., 23:45 ч. UTC

News

UBS initiated coverage on CRISPR Therapeutics AG with a Neutral rating and set a price target of $52.00, contributing to a modest after-market decline.

13.10.2026 г., 20:07 ч. UTC

Correlated Moves

CRISPR Therapeutics AG shares are declining amid a broader biotechnology sector downturn, with the SPDR S&P Biotech ETF (XBI) also lower due to key holdings' drops.

12.10.2026 г., 22:51 ч. UTC

CRISPR Therapeutics AG shares advanced modestly in after-market trading, despite a notable decline from an earlier high following Monday's close.

9.10.2026 г., 23:25 ч. UTC

CRISPR Therapeutics AG's shares showed little change during after-market hours, trading within a narrow range and remaining below their 20-day moving average.

8.10.2026 г., 23:05 ч. UTC

Event

CRISPR Therapeutics AG will present Phase 1b trial data for CTX310® at the American Heart Association Scientific Sessions 2026, scheduled for November 6-9, 2026.

7.10.2026 г., 23:00 ч. UTC

CRISPR Therapeutics AG is higher in after-market trading, recovering from three lower sessions, with cumulative returns peaking at 1.11% before retracing slightly to 1.05%.

6.10.2026 г., 20:00 ч. UTC

Correlated Moves

The ARK Genomic Revolution ETF fell sharply as key holdings Guardant Health and Absci Corp. declined following disappointing study results.

5.10.2026 г., 23:15 ч. UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, positioned above its 20-day moving average and near the upper end of its one-month trading range.

2.10.2026 г., 20:07 ч. UTC

News

CRISPR Therapeutics AG shares fell sharply, pulling back from earlier gains amid a broader market trend of slight declines since Thursday's close.

1.10.2026 г., 20:07 ч. UTC

CRISPR Therapeutics AG advanced during Thursday's trading session, reflecting a modest gain since Wednesday's close, despite earlier pulling back from a session high.

30.09.2026 г., 23:01 ч. UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours following a pullback from an earlier peak during the regular session.

29.09.2026 г., 23:06 ч. UTC

CRISPR Therapeutics AG's shares were roughly flat during after-market hours, trading within a narrow range and above the 20-day moving average.

28.09.2026 г., 22:31 ч. UTC

CRISPR Therapeutics AG advanced during after-market hours, continuing its upward movement despite a recent trend of lower trading in the broader biotechnology sector.

25.09.2026 г., 23:00 ч. UTC

CRISPR Therapeutics AG sees a modest increase in after-market trading following Friday's close, positioned around the midpoint of its one-month trading range.

24.09.2026 г., 23:00 ч. UTC

CRISPR Therapeutics AG is trading lower in after-market hours, reaching its lowest point since Thursday amid rising Treasury yields and geopolitical tensions.

23.09.2026 г., 20:02 ч. UTC

News
Correlated Moves

Shares of CRISPR Therapeutics AG are declining sharply following Anthropic's announcement of a novel enzyme system with similarities to CRISPR, raising competitive concerns.

22.09.2026 г., 23:31 ч. UTC

CRISPR Therapeutics AG is rising in after-market trading, gaining ground since Tuesday's close and remaining above its 20-day moving average.

21.09.2026 г., 23:51 ч. UTC

CRISPR Therapeutics AG is trading modestly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month range.

19.09.2026 г., 00:02 ч. UTC

Correlated Moves

CRISPR Therapeutics AG is advancing in after-market trading, likely in sympathy with Editas Medicine Inc, amid broader economic concerns.

18.09.2026 г., 23:01 ч. UTC

CRISPR Therapeutics AG is advancing in after-market trading, moving higher alongside the broader market, following a peak return earlier in the session.

17.09.2026 г., 23:51 ч. UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

16.09.2026 г., 23:16 ч. UTC

CRISPR Therapeutics AG is declining in after-market hours, trading near the lower end of its one-month range and below its 20-day moving average.

15.09.2026 г., 23:01 ч. UTC

CRISPR Therapeutics AG shares are higher in after-market hours, reflecting overall market momentum despite a decline in the New York Empire State Manufacturing Index.

Сравнение с други в отрасъла

Ценова промяна

CRISPR Therapeutics AG Прогноза

Ценова цел

By TipRanks

42.36% нагоре

12-месечна прогноза

Среден 71.167 USD  42.36%

Висок 110 USD

Нисък 45 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за CRISPR Therapeutics AG през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

7

Купи

6

Задържане

0

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat